Biotech GSK gives Clover adjuvant for vaccine against ‘indispensable’ COVID-19 protein

GlaxoSmithKline has struck a deal to provide its pandemic adjuvant to Clover Biopharmaceuticals for use in a COVID-19 vaccine candidate. Clover is one of a clutch of organizations working to tackle COVID-19 by targeting a protein the novel coronavirus needs to enter host cells. China’s Clover, which is based 600 miles west of the focal point of…